CYP cynata therapeutics limited

9.68%

17.0¢

CYP 2021 - The year ahead, page-92

First 92 Last

Share
Profile

Follow
sigmadelta

10,295 Posts.

999

21/01/21

23:44

Post #: 50358225
Share

Originally posted by JB1975: ↑

" with the 440 patient Phase 3 OA trial to give the manufacturing it’s first minor test."

" While the company have designed the manufacturing process with scalability as a priority (per their presentations), commercial partners will be responsible for upscaling upon acquisition of each indication’s licence, which is standard among these agreements"

These agreements must be somewhat new and novel given there has never been a Cymerus process before, seems to me. Seems they are what Ross can make them be..

". As this represents a large up-front cost, being able to validity of the scalability will be paramount. In a 15 person trial, it is easy to sweep any problems under the rug. In a 440 person trial with ~1000 doses, this is not as simple and you can be sure that potential partners will be watching the roll-out with a keen eye."

Actually I agree with you about large up front costs making potential partners cautious about committing prior to getting proofs of scalability, but not that a mere 440 person trial with around a thousand doses results to be known in over two years time is likely to be enough proof.

I think CYP needs faster trial results on some other indication but also to demonstrate a proof in principle that many thousands of doses can be made in commercially relevant clincial timeframes (before the OA resuts come in). This could be done with a demonstration that CYP cells work (in an animal model say) after coming though a 3D manufacturing process. It need not be done at huge scale (not a Fujifilm 20,000 litre bioreactor) but I think it needs to be done in a scaled down prototype (maybe 5litres or 50 litres) with the proper media and microcarriers to demonstrate it can be done sooner rather than later.

Expand

All of this would be so much simpler if only the company would seriously try to establish trust with the investment community, and stop wasting time pissing around with their own ownership and salary as their main priority. They might even have got full take up of the entitlement.

CYP Price at posting: 69.0¢ Sentiment: Sell Disclosure: Held
6 Upvote

2 Great analysis

Reply

Top Stories

AII

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

First 92 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 17.0¢		Change 0.015(9.68%)		Mkt cap ! $38.41M

Open	High	Low	Value	Volume
15.5¢	17.0¢	15.5¢	$47.10K	289.1K

Buyers (Bids)

No.	Vol.	Price($)
1	50000	16.5¢

Sellers (Offers)

Price($)	Vol.	No.
17.0¢	23813	3

View Market Depth

No.	Vol.	Price($)
1	50000	0.165
4	47240	0.155
4	161673	0.150
1	5000	0.145
2	45000	0.140

Price($)	Vol.	No.
0.170	18813	2
0.175	55250	1
0.180	62619	3
0.185	35990	1
0.195	19300	1

Last trade - 16.10pm 27/06/2025 (20 minute delay)

CYP (ASX) Chart

CYP 2021 - The year ahead, page-92

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Australia’s gas crisis is here – and dying coal plants aren’t helping

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Monash IVF shares cater 25% – Disaster or deep-value play?

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

CYP 2021 - The year ahead, page-92

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Australia’s gas crisis is here – and dying coal plants aren’t helping

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Monash IVF shares cater 25% – Disaster or deep-value play?

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News